Clinical Trial Detail

NCT ID NCT02573220
Title Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements yes
Sponsors University of Chicago
Indications

colorectal cancer

Therapies

Cetuximab + FOLFIRI

Age Groups: adult

Additional content available in CKB BOOST